Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Chuikyo Approves 8 Drugs for Inclusion in NHI Price List
June 5, 2006
- Suzuken: Addition of Astis Boosts Sales
June 5, 2006
- Chuikyo Approves NHI Price Listing of Nicotine Patch
June 5, 2006
- Alfresa HD: Sales Exceed \1.4 Trillion
June 5, 2006
- New Dosage Forms of Itraconazole, Moxifloxacin Recommended for Approval
June 5, 2006
- Toho: Solid Growth in Sales, Profits
June 5, 2006
- Avonex, Baraclude Recommended for Approval
June 5, 2006
- Hokuyaku, Takeyama to Integrate Business in September
June 5, 2006
- Mr Niwa Offers 8 Proposals for Social Security Reform
June 5, 2006
- Risk from TGN1412 Could Have Been Predicted: Cambridge Professor
June 5, 2006
- Huntingdon Life Sciences to Expand Japanese Business: Mr Cass
June 5, 2006
- Korosho to Develop Individualized Treatment for Esophageal Cancer
June 5, 2006
- REGULATORY NEWS IN BRIEF
June 5, 2006
- New Requirement Related to IRBs May Delay Clinical Trials: Medical Associations
June 5, 2006
- CMIC Allies with KineMed to Add Value to Aborted Compounds
June 5, 2006
- R&D NEWS IN BRIEF
June 5, 2006
- Sales Force Effectiveness Japan
June 5, 2006
- Vesicare Drug of Choice for OAB: Prof. Yamaguchi
June 5, 2006
- INTERPHEX JAPAN
June 5, 2006
- Early Discovery, Continuous Treatment with Anticoagulants Important for Cerebral Infarction
June 5, 2006
ページ
Japan will overhaul its R&D tax credit regime in its FY2026 reform, introducing a new strategic category alongside existing frameworks.…
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…